<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12737/article_590823a49422a0.54537639</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-195</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА</subject></subj-group></article-categories><title-group><article-title>Редокс-чув-ствительная система антиоксидант-респонсив-ного элемента как новая мишень для лечения туберкулеза</article-title><trans-title-group xml:lang="en"><trans-title>Redox-sensitive system of the antioxidant-responsive element as a new target for tuberculosis treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кожин</surname><given-names>П. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozhin</surname><given-names>P. M.</given-names></name></name-alternatives><email xlink:type="simple">kozhinpm@centercem.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зенков</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Zenkov</surname><given-names>N. K.</given-names></name></name-alternatives><email xlink:type="simple">zenkovnk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чечушков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chechushkov</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">achechushkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайцева</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaytseva</surname><given-names>N. S.</given-names></name></name-alternatives><email xlink:type="simple">nszaitseva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кандалинцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kandalintseva</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">aquaphenol@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меньщикова</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Menshchikova</surname><given-names>E. B.</given-names></name></name-alternatives><email xlink:type="simple">lemen@centercem.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт экспериментальной и клинической медицины»</institution></aff><aff xml:lang="en"><institution>Research Institute of Experimental and Clinical Medicine</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВПО «Новосибирский государственный педагогический университет»</institution></aff><aff xml:lang="en"><institution>Novosibirsk State Pedagogical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>05</month><year>2016</year></pub-date><volume>1</volume><issue>3(2)</issue><fpage>92</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кожин П.М., Зенков Н.К., Чечушков А.В., Зайцева Н.С., Кандалинцева Н.В., Меньщикова Е.Б., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Кожин П.М., Зенков Н.К., Чечушков А.В., Зайцева Н.С., Кандалинцева Н.В., Меньщикова Е.Б.</copyright-holder><copyright-holder xml:lang="en">Kozhin P.M., Zenkov N.K., Chechushkov A.V., Zaytseva N.S., Kandalintseva N.V., Menshchikova E.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/195">https://www.actabiomedica.ru/jour/article/view/195</self-uri><abstract><p>На модели микобактериального гранулематозного воспаления in vitro исследовано влияние индукции редоксчувствительной сигнальной системы антиоксидант-респонсивного элемента Keap1/Nrf2/ARE на динамику образования гранулём. Обнаружено, что активация системы Keap1/Nrf2/ARE приводит к ускорению процессов образования гранулём, которые затем сменяются процессами их диссоциации, что позволяет рассматривать систему Keapl/Nrß/ARE как новую терапевтическую мишень в терапии туберкулеза.</p></abstract><trans-abstract xml:lang="en"><p>The emergence of drug-resistant TB caused by resistance to antibiotic strains of bacteria, prompted to search for new "organism-oriented" ("host-targeted") adjuvant treatment strategies. Free radical oxidation plays an important role in the development and exacerbation of the pathological process. The main system of cell protection from oxidative stress is the redox-sensitive signaling system of the antioxidant-responsive element of the Keap1/Nrf2/ARE, which includes the transcription factor Nrf2, which is under constant control of a repressor protein Keapl. Nrf2 regulates the expression of genes containing the antioxidant-responsive element ARE in their promoters, Keapl is a kind of molecular "sensor" of modifications in the intracellular homeostasis. The inextricable link between these molecular structures allows combining them into a single redox-sensitive signaling system Keap1/Nrf2/ARE. Nrf2 modulates resistance of the organism to various infections: activation of Nrf2 prevents the penetration and replication of influenza A virus, contributes to resistance to various bacterial agents (Salmonella typhimurium, Pseudomonas aeruginosa). The aim of this work was to study the influence of induction system Keap1/Nrf2/ARE on the formation of mycobacterial granulomas in vitro. In vitro model was used to study effect of induction of the redox-sensitive signaling system Keap1/Nrf2/ARE in time course of granuloma formation. It was found that the activation of Keap1/Nrf2/ARE system led to acceleration of granuloma formation, which was then replaced by the dissociation process. These data allowed us to consider Keapl/Nrß/ARE system as a new therapeutic target in the tuberculosis treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гранулематозное воспаление</kwd><kwd>туберкулез</kwd><kwd>макрофаги</kwd><kwd>система Keap1/Nrf2/ARE</kwd><kwd>ТС-13</kwd></kwd-group><kwd-group xml:lang="en"><kwd>granulomatous inflammation</kwd><kwd>tuberculosis</kwd><kwd>macrophages</kwd><kwd>Keap1/Nrf2/ARE system</kwd><kwd>TS-13</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Зенков Н.К., Меньщикова Е.Б., Ткачёв В.О. Редокс-чувствительная сигнальная система Кеарі/Nrf 2/ARE как фармакологическая мишень // Биохимия. 2013. - Т. 78, № 1. - C. 27-47</mixed-citation><mixed-citation xml:lang="en">Зенков Н.К., Меньщикова Е.Б., Ткачёв В.О. Редокс-чувствительная сигнальная система Кеарі/Nrf 2/ARE как фармакологическая мишень // Биохимия. 2013. - Т. 78, № 1. - C. 27-47</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кожин П.М., Зенков Н.К., Лемза А.Е., Чечушков А.В., Зайцева Н.С., Кандалинцева Н.В., Меньщикова Е.Б. Влияние индукции редокс-чувствительной системы Keap1/Nrf2/ARE на классическую активацию макрофагов // Сибирский научный медицинский журнал. - 2015. - № 6. - C. 37-44</mixed-citation><mixed-citation xml:lang="en">Кожин П.М., Зенков Н.К., Лемза А.Е., Чечушков А.В., Зайцева Н.С., Кандалинцева Н.В., Меньщикова Е.Б. Влияние индукции редокс-чувствительной системы Keap1/Nrf2/ARE на классическую активацию макрофагов // Сибирский научный медицинский журнал. - 2015. - № 6. - C. 37-44</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Меньщикова Е.Б., Зенков Н.К., Чечушков А.В., Кожин П.М., Черданцева Л.А., Шаркова Т.В., Потапова О.В., Любимов Г.Ю., Любимова Г.А., Ягунов С.Е. Участие активированных кислородных метаболитов и редокс-чувствительной сигнальной системы Keap1/ Nrf2/ARE в развитии гранулематозного воспаления // Сибирский научный медицинский журнал. - 2015. -№ 2. - С. 32-36</mixed-citation><mixed-citation xml:lang="en">Меньщикова Е.Б., Зенков Н.К., Чечушков А.В., Кожин П.М., Черданцева Л.А., Шаркова Т.В., Потапова О.В., Любимов Г.Ю., Любимова Г.А., Ягунов С.Е. Участие активированных кислородных метаболитов и редокс-чувствительной сигнальной системы Keap1/ Nrf2/ARE в развитии гранулематозного воспаления // Сибирский научный медицинский журнал. - 2015. -№ 2. - С. 32-36</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Просенко А.Е., Клепикова С.Ю., Кандалинцева Н.В., Дюбченко О.И., Душкин М.И., Зенков Н.К., Меньщикова Е.Б. Синтез и исследование антиоксидантных свойств новых водорастворимых серосодержащих фенольных соединений // Бюлл. ВСНЦ СО РАМН. -2001. - № 1. - С. 114-126</mixed-citation><mixed-citation xml:lang="en">Просенко А.Е., Клепикова С.Ю., Кандалинцева Н.В., Дюбченко О.И., Душкин М.И., Зенков Н.К., Меньщикова Е.Б. Синтез и исследование антиоксидантных свойств новых водорастворимых серосодержащих фенольных соединений // Бюлл. ВСНЦ СО РАМН. -2001. - № 1. - С. 114-126</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Harvey CJ, Thimmulappa RK, Sethi S (2011). Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci. Transl. Med., 3 (78), 78ra32</mixed-citation><mixed-citation xml:lang="en">Harvey CJ, Thimmulappa RK, Sethi S (2011). Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci. Transl. Med., 3 (78), 78ra32</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lyamina SV, Kruglov SV, Vedenikin TY, Borodovitsyna OA, Suvorova IA, Shimshelashvili ShL, Malyshev IY (2012). Alternative reprogramming of M1/M2 phenotype of mouse peritoneal macrophages in vitro with inter-feron-γ and interleukin-4. Bull. Exp. Biol. Med., 152 (4), 548-551.</mixed-citation><mixed-citation xml:lang="en">Lyamina SV, Kruglov SV, Vedenikin TY, Borodovitsyna OA, Suvorova IA, Shimshelashvili ShL, Malyshev IY (2012). Alternative reprogramming of M1/M2 phenotype of mouse peritoneal macrophages in vitro with inter-feron-γ and interleukin-4. Bull. Exp. Biol. Med., 152 (4), 548-551.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Olagnier D, Lavergne RA, Meunier E, Lefevre L, Dardenne C, Aubouy A, Pipy B (2011). Nrf2, a PPARy alternative pathway to promote CD36 expression on inflammatory macrophages: implication for malaria. PLoS Pathog., 7 (9), e1002254.</mixed-citation><mixed-citation xml:lang="en">Olagnier D, Lavergne RA, Meunier E, Lefevre L, Dardenne C, Aubouy A, Pipy B (2011). Nrf2, a PPARy alternative pathway to promote CD36 expression on inflammatory macrophages: implication for malaria. PLoS Pathog., 7 (9), e1002254.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, Altare F (2004). An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cellular microbiology, 6 (5), 423-433.</mixed-citation><mixed-citation xml:lang="en">Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, Altare F (2004). An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cellular microbiology, 6 (5), 423-433.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rajendran P, Nandakumar N, Rengarajan T, Palaniswami R, Gnanadhas EN, Lakshminarasaiah U, Nishi gaki I (2014). Antioxidants and human diseases. Clinica Chimica Acta, 436, 332-347.</mixed-citation><mixed-citation xml:lang="en">Rajendran P, Nandakumar N, Rengarajan T, Palaniswami R, Gnanadhas EN, Lakshminarasaiah U, Nishi gaki I (2014). Antioxidants and human diseases. Clinica Chimica Acta, 436, 332-347.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Schwegmann A, Brombacher F (2008). Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal., 1 (29), re8.</mixed-citation><mixed-citation xml:lang="en">Schwegmann A, Brombacher F (2008). Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal., 1 (29), re8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stefanson AL, Bakovic M (2014). Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients, 6 (9), 3777-3801.</mixed-citation><mixed-citation xml:lang="en">Stefanson AL, Bakovic M (2014). Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients, 6 (9), 3777-3801.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tugal D, Liao X, Jain MK (2013). Transcriptional control of macrophage polarization.Arterioscler. Thromb. Vasc. Biol, 33 (6), 1135-1144.</mixed-citation><mixed-citation xml:lang="en">Tugal D, Liao X, Jain MK (2013). Transcriptional control of macrophage polarization.Arterioscler. Thromb. Vasc. Biol, 33 (6), 1135-1144.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov., 12 (5), 388-404.</mixed-citation><mixed-citation xml:lang="en">Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov., 12 (5), 388-404.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
